This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Center

Paul Dawidczyk
VP, Regulatory Affairs CMC at Moderna Therapeutics


Mr. Dawidczyk joined Moderna in May 2017 and is currently the Vice President of Regulatory Affairs CMC for Moderna’s rare disease, infectious disease, oncology and cardiovascular programs. Mr. Dawidczyk has over 30 years of pharmaceutical and biotechnology experience with proteins, messenger RNA, monoclonal antibodies, small molecules, cellular therapies, oligonucleotides, IVDs, combination products (biologics/device) and medical devices. Prior to joining Moderna, Mr. Dawidczyk was the Director of Regulatory Affairs CMC supporting the enzyme replacement therapy programs at Sanofi Genzyme. Mr. Dawidczyk received a BS in Biochemistry from the University of Massachusetts at Amherst.

Agenda Sessions

  • CMC Regulatory Strategies for mRNA Vaccines